Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sebelipase alfa regulatory update

FDA granted breakthrough therapy designation for Synageva's sebelipase alfa to treat early onset lysosomal

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE